t cell acute lymphoblastic leukemia all cell line molt 4  (ATCC)

Journal: International Journal of Molecular Sciences

Article Title: Targeting Oxidative Phosphorylation with a Novel Thiophene Carboxamide Increases the Efficacy of Imatinib against Leukemic Stem Cells in Chronic Myeloid Leukemia

doi: 10.3390/ijms252011093

Figure Lengend Snippet: NK-128 inhibits the proliferation of CML and Philadelphia chromosome-positive acute lymphoblastic leukemia cell lines. ( A ) Cells were incubated with NK-128 and cell numbers were counted on Days 4 and 8. The number of viable cells is shown. NK-128 inhibited the proliferation of BV173 ( p < 0.01) and SUP-B15 ( p < 0.05) cells significantly, even at concentrations as low as 0.1 μM. (* p < 0.05, ** p < 0.01). ( B ) Experimental scheme showing the generation of the K562 xenograft model using NOD/Shi-scid IL-2Rγ KO Jic mice. On Day 0, K562 cells (4.0 × 10 6 cells/mouse) were injected subcutaneously into NOD/Shi-scid IL-2Rγ KO Jic mice. Daily ip administration of the vehicle and NK-128 began on Day 8. ( C ) Tumor growth curves and ( D ) body weight for each group; vehicle (black; n = 10), 10 mg/kg NK-128 (blue; n = 10), and 20 mg/kg NK-128 (red; n = 10).

Article Snippet: The Philadelphia chromosome-positive (Ph + ) acute lymphoblastic leukemia (ALL) cell line SUP-B15 was purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA).

Techniques: Incubation, Injection

Journal: International Journal of Molecular Sciences

Article Title: Targeting Oxidative Phosphorylation with a Novel Thiophene Carboxamide Increases the Efficacy of Imatinib against Leukemic Stem Cells in Chronic Myeloid Leukemia

doi: 10.3390/ijms252011093

Figure Lengend Snippet: Combination therapy with imatinib and NK-128 inhibits the proliferation of CML cell lines and Philadelphia chromosome-positive acute lymphoblastic leukemia cell lines to a greater extent than imatinib alone. ( A ) CML and Ph + ALL cell lines were treated with medium (black), imatinib (blue) or a combination of imatinib and 0.1 μM NK-128 (red). The concentration of imatinib was 0.25 μM for K562, 0.2 μM for MYL, 0.1 μM for BV173, 0.4 μM for SUP-B15, and 1 μM for MYL-R. The combination of NK-128 plus imatinib also inhibited the proliferation to a greater extent than imatinib alone. (** p < 0.01) ( B ) Each cell line was treated with or without NK-128 and imatinib (IM) for 3 days. The number of cells stained with APC-annexin V was measured by flow cytometric analysis, as described in the . Results are the mean of three independent experiments with SD (* p < 0.05, ** p < 0.01).

Article Snippet: The Philadelphia chromosome-positive (Ph + ) acute lymphoblastic leukemia (ALL) cell line SUP-B15 was purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA).

Techniques: Concentration Assay, Staining

Journal: International Journal of Molecular Sciences

Article Title: Targeting Oxidative Phosphorylation with a Novel Thiophene Carboxamide Increases the Efficacy of Imatinib against Leukemic Stem Cells in Chronic Myeloid Leukemia

doi: 10.3390/ijms252011093

Figure Lengend Snippet: ATP and lactate production by K562, BV173, MYL, and SUP-B15 cells. Oligomycin inhibits OXPHOS, and 2-DG inhibits glycolysis. ATP and lactate production levels were determined in K562 and MYL cell lines, which are less sensitive to NK-128 ( A ) or in the sensitive cell lines, BV173 and SUP-B15 ( B ), as described in the . The main metabolic pathways of K562 and MYL are glycolysis-dependent. Conversely, those of BV173 and SUP-B15 are OXPHOS-dependent. NK-128 inhibits the production of ATP in BV173 and SUP-B15 cells, which are mainly OXPHOS dependent.

Article Snippet: The Philadelphia chromosome-positive (Ph + ) acute lymphoblastic leukemia (ALL) cell line SUP-B15 was purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA).

Techniques: